| Methods |
Randomized, double blinded, placebo‐controlled trial |
| Participants |
Vascular surgery patients |
| Interventions |
N‐acetylcysteine 2400 mg oral before surgery then 1200 mg iv for 48 hrs postop versus no treatment |
| Outcomes |
occurrence of acute renal failure |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not stated. |
| Allocation concealment (selection bias) |
High risk |
N‐acetylcysteine versus no treatment. |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Stated "double‐blinded" but compared N‐acetylcysteine versus no treatment. |
| Selective reporting (reporting bias) |
Low risk |
|
| Other bias |
Low risk |
|
